AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.40B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.57M
Average 0.76M
ANAB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
AnaptysBio, Inc.NASDAQ: ANAB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $52.88M (cash outflow) rose 34.5% year over year, ahead of the -81.0% change in trailing-twelve-month net income.
Context
- Net income amounted to 21.1% of revenue in FY2025, down 138.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $132.02M (+166.1%) for the fiscal year ending Dec 2026, a step up from the +134.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$52.88M-206.6% QoQ
- Last fiscal yearDec 2025
- $49.61M+134.2% YoY
- LTMMar 2026
- -$26.79M-81.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +34.5% | -18.9% | -53.4 pp |
| 1 year | +134.2% | +166.1% | +31.9 pp |
| 3-year CAGR | — | +63.9% | — |
| 5-year CAGR | +39.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 49.61M USD
- Year-over-year change
- +134.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.61M | +134.2% |
| FY2024 | 2024-12-31 | (145.23M) | +11.2% |
| FY2023 | 2023-12-31 | (163.62M) | -27.1% |
| FY2022 | 2022-12-31 | (128.72M) | -122.7% |
| FY2021 | 2021-12-31 | (57.8M) | — |
Net Income vs competitors
How ANAB compares with its peers on the latest reported figures
- ANAB's LTM Mar 2026 net income of $26.79M is the smallest of the 10 companies compared; the peer median is $87.07M.
- Its year-over-year change of -81.0% is the lowest of 10, against a peer median of +21.4%.
- Net income amounts to 11.5% of revenue for ANAB, versus a peer median of 4003.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $508.96M | +9.5% | +33.8% | 7173.5% | |
| LTM Mar 2026 | $259.47M | +76.5% | +66.1% | — | |
| LTM Mar 2026 | $196.48M | +17.4% | +13.3% | — | |
| LTM Jun 2026 | $192.25M | +67.5% | +78.6% | 10097.0% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M | +21.4% | +12.6% | — |
| LTM Jun 2026 | $71.19M | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| FY2025 | $55.48M | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Mar 2026 | $26.79M | -81.0% | — | 11.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ANAB) | $87.07M | +21.4% | +15.9% | 4003.0% | |
Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | 49.61M |
| Depreciation & Amortization | 2.09M | 2.34M | 2.38M | 2.4M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.35M | 27.36M | 33.21M | 34.05M | 36.07M |
| Change in Working Capital | (7.49M) | 6.84M | (324K) | (66.33M) | (80.73M) |
| Accounts Receivables | (876K) | (543K) | (5.43M) | (33.91M) | 6.92M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.74M) | 9.7M | 10.94M | (33.84M) | (87.33M) |
| Other Working Capital | (1.87M) | (2.32M) | (5.83M) | 1.43M | (313K) |
| Other Non-Cash Items | 1.93M | 18.6M | 7.56M | 39.77M | 12.31M |
| Operating Cash Flow | (45.92M) | (73.59M) | (120.8M) | (135.34M) | 19.7M |
| Capital Expenditures | (1.37M) | (358K) | (807K) | (358K) | (87K) |
| Acquisitions (Net) | 0 | 394.49M | 0 | 0 | 0 |
| Purchases of Investments | (118.66M) | (802.5M) | (303.92M) | (380.38M) | (196.41M) |
| Sales of Investments | 158.85M | 408.02M | 449.48M | 476.13M | 424.53M |
| Other Investing Activities | 15K | (394.49M) | 0 | 0 | 0 |
| Investing Cash Flow | 38.84M | (394.85M) | 144.75M | 95.4M | 228.03M |
| Debt Repayment | 0 | 0 | (11.73M) | 34.77M | (76.8M) |
| Common Stock Issued | 2.55M | 11.83M | 2.47M | 100.84M | 14.26M |
| Common Stock Repurchased | 0 | 0 | (50M) | (456K) | (68.63M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 249.75M | 32.19M | (43K) | (8.1M) | (1.45M) |
| Financing Cash Flow | 252.3M | 44.02M | (59.3M) | 127.05M | (132.61M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 245.21M | (424.42M) | (35.34M) | 87.12M | 115.12M |
| Free Cash Flow | (47.29M) | (73.95M) | (121.61M) | (135.7M) | 19.61M |
AnaptysBio, Inc.
NASDAQ:ANAB
Intrinsic Alpha fair value
Locked
Current Price
$47.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.